Genital infection with type 2 herpes simplex virus. A common venereal disease

Labial agglutination secondary to a herpes simplex II infection

A case is described of a young woman with labial agglutination secondary to a herpes simplex II infection that was successfully treated with laser vaporization.

Synergism among BIOLF-62, phosphonoformate, and other antiherpetic compounds

9-[[2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine (BIOLF-62) is highly synergistic with either phosphonoformate or phosphonoacetate when used in combination against herpes simplex virus types 1 and 2 in vitro. Acycloguanosine did not show significant synergism with these two compounds. Bromovinyldeoxyuridine and phosphonoformate were highly synergistic against herpes simplex virus type 2, but not against type 1.

Herpes simplex virus type 2 and cancer of the prostate

A seroepidemiologic study was performed to determine if there was an association between antibodies to herpes simplex virus type 2 and cancer of the prostate, similar to that reported for herpes simplex virus type 2 and cervical carcinoma. No significant difference in herpes simplex virus type 2 antibodies was seen between patients with cancer of the prostate and those with benign prostatic hypertrophy. Further studies are needed to define the possible role of herpes simplex virus type 2 in the etiology of cancer of the prostate.